{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:01:26Z","timestamp":1780992086170,"version":"3.54.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.12.018","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:35:31Z","timestamp":1767425731000},"page":"128-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["SOHO State of the Art Updates and Next Questions | SOHO 2025 Next Questions: Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"26","author":[{"given":"Hannah","family":"Goulart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2025.12.018_bib0001","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-473298","article-title":"Treatment of older patients with ALL","volume":"45","author":"Jabbour","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10506","key":"10.1016\/j.clml.2025.12.018_bib0002","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clml.2025.12.018_bib0003","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajh.27708","article-title":"Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.clml.2025.12.018_bib0004","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1038\/s41375-021-01277-3","article-title":"Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms","volume":"35","author":"Short","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.12.018_bib0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ajh.27576","article-title":"Hyper-CVAD and sequential blinatumomab without and with inotuzumab in young adults with newly diagnosed Philadelphia chromosome-negative b-cell acute lymphoblastic leukemia","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.018_bib0006","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2025.12.018_bib0007","doi-asserted-by":"crossref","first-page":"e878","DOI":"10.1016\/S2352-3026(22)00285-X","article-title":"Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial","volume":"9","author":"Jabbour","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0008","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1182\/blood-2025-1567","article-title":"The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: four-year follow-up of a phase 2 study","volume":"146","author":"Goulart","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0009","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1182\/blood-2025-1566","article-title":"Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis","volume":"146","author":"Goulart","year":"2025","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.12.018_bib0010","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajh.26156","article-title":"Acute lymphoblastic leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980-2017","volume":"96","author":"Sasaki","year":"2021","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.12.018_bib0011","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol"},{"issue":"15","key":"10.1016\/j.clml.2025.12.018_bib0012","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0013","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/blood-2024-207745","article-title":"Older age and TP53 mutations are predictors for the development of therapy-related myeloid neoplasms in adults undergoing frontline therapy for acute lymphoblastic leukemia","volume":"144","author":"Santos Azevedo","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0014","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1182\/blood-2025-5131","article-title":"Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia","volume":"146","author":"Goulart","year":"2025","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.clml.2025.12.018_bib0015","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1200\/JCO-25-00307","article-title":"Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed b-cell all: alliance study a041703 cohort 1 results","volume":"43","author":"Wieduwilt","year":"2025","journal-title":"J Clin Oncol"},{"issue":"444","key":"10.1016\/j.clml.2025.12.018_bib0016","first-page":"1","volume":"146","author":"Wieduwilt","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0017","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1182\/blood-2024-201784","article-title":"CD19-CAR T cells as definitive consolidation for older adults with B-cell acute lymphoblastic leukemia in first complete remission: a pilot study","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0018","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13045-023-01409-5","article-title":"The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades","volume":"16","author":"Jabbour","year":"2023","journal-title":"J Hematol Oncol"},{"issue":"21","key":"10.1016\/j.clml.2025.12.018_bib0019","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1001\/jama.2024.4783","article-title":"Ponatinib vs imatinib in frontline Philadelphia chromosome-positive acute lymphoblastic leukemia: a randomized clinical trial","volume":"331","author":"Jabbour","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-025-01709-y","article-title":"Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab","volume":"18","author":"Short","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0021","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood-2025-1571","article-title":"Blinatumomab and ponatinib demonstrates ongoing efficacy as frontline therapy in Philadelphia positive B-cell acute lymphoblastic leukemia: long-term follow-up from a phase 2 Study","volume":"146","author":"Goulart","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.12.018_bib0022","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1200\/JCO.23.01075","article-title":"Long-term results of the dasatinib-blinatumomab protocol for adult Philadelphia-positive ALL","volume":"42","author":"Foa","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.12.018_bib0023","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2025.0674","article-title":"Dasatinib and CAR T-cell therapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a nonrandomized clinical trial","volume":"11","author":"Zhang","year":"2025","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.clml.2025.12.018_bib0024","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1007\/s00277-024-06027-w","article-title":"Olverembatinib treatment in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"103","author":"Zhu","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2025.12.018_bib0025","article-title":"Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0026","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2024.5157","article-title":"Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: a phase 1b randomized clinical trial","volume":"11","author":"Jabbour","year":"2025","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.clml.2025.12.018_bib0027","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1182\/bloodadvances.2022007378","article-title":"High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse","volume":"6","author":"Short","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2025.12.018_bib0028","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1182\/bloodadvances.2021006727","article-title":"Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods","volume":"6","author":"Kotrova","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0029","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2025.12.018_bib0030","doi-asserted-by":"crossref","unstructured":"Goekbuget N SF, Nachtkamp K, et al. Chemotherapy or stem cell transplantation in adult high risk Ph\/BCR::ABL1-negative ALL patients with early MRD negativity: results of the randomized GMALL trial 08\/2013. Blood;144:1:961.","DOI":"10.1182\/blood-2024-199060"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0031","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41408-025-01373-y","article-title":"Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL","volume":"15","author":"Short","year":"2025","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0032","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood-2024-206184","article-title":"Clearance of very low levels of measurable residual disease with blinatumomab significantly improves outcomes in B-Cell acute lymphoblastic leukemia","volume":"144","author":"Nguyen","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2025.12.018_bib0033","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/ajh.26949","article-title":"Ultrasensitive NGS MRD assessment in Ph+ ALL: prognostic impact and correlation with RT-PCR for BCR::ABL1","volume":"98","author":"Short","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0034","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.clml.2025.12.018_bib0035","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0036","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2025-551","volume":"146","author":"Maroun","year":"2025","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2025.12.018_bib0037","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.24.00108","article-title":"Significance of measurable residual disease in adult Philadelphia chromosome-positive ALL: A GRAAPH-2014 study","volume":"42","author":"Kim","year":"2024","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2025.12.018_bib0038","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35773","article-title":"Treatment-free remission in nontransplanted patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"131","author":"Kugler","year":"2025","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2025.12.018_bib0039","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2025.12.018_bib0040","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.12.018_bib0041","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-Hyper-CVD for patients with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0042","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/blood-2024-210501","article-title":"Updated results of the combination of mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab in patients with relapsed\/refractory B-Cell ALL","volume":"144","author":"Habib","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.018_bib0043","doi-asserted-by":"crossref","first-page":"S284","DOI":"10.1016\/S2152-2650(24)01140-6","article-title":"ALL-808 very promising results of the dose dense (D-D) Mini-Hyper-CVD-inotuzumab-blinatumomab phase 2 trial in patients with relapsed-refractory acute lymphoblastic leukemia","volume":"24","author":"Jabbour","year":"2024","journal-title":"Clin Lymphoma Myeloma and Leuk"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0044","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1182\/blood-2025-3350","article-title":"Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab","volume":"146","author":"Goulart","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2025.12.018_bib0045","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"10.1016\/j.clml.2025.12.018_bib0046","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clml.2025.12.018_bib0047","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-Cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0048","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2024-194508","article-title":"Obecabtagene autoleucel (obe-cel) for adult relapsed\/refractory B-Cell acute lymphoblastic leukemia (R\/R B-ALL): deep molecular remission may predict better outcomes","volume":"144","author":"Jabbour","year":"2024","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.clml.2025.12.018_bib0049","first-page":"S504","volume":"42","author":"Jabbour","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0050","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2025-2715","article-title":"Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: a rocca analysis","volume":"146","author":"Valtis","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.018_bib0051","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2025.43.16_suppl.6543","article-title":"Brexucabtagene autoleucel (Brexu-cel) as consolidation treatment in adults with B-cell acute lymphoblastic leukemia","volume":"43","author":"Khaire","year":"2025","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.12.018_bib0052","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/S2352-3026(25)00144-9","article-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","volume":"12","author":"Jabbour","year":"2025","journal-title":"Lancet Haematol"},{"issue":"12","key":"10.1016\/j.clml.2025.12.018_bib0053","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1038\/s41375-024-02414-4","article-title":"Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma","volume":"38","author":"Ravandi","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.clml.2025.12.018_bib0054","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1002\/ajh.27094","article-title":"Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy","volume":"98","author":"Zhang","year":"2023","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.12.018_bib0055","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.12.018_bib0056","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.12.018_bib0057","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1182\/blood.2025028387","article-title":"Phase 1\/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed\/refractory T-cell malignancies","volume":"146","author":"Ghobadi","year":"2025","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.12.018_bib0058","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2024-201362","article-title":"CD7 CAR T-Cell therapy in relapsed or refractory t-cell acute lymphoblastic leukemia: a retrospective study","volume":"144","author":"Pan","year":"2024","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025043253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:44:53Z","timestamp":1780991093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025043253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025043253"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | SOHO 2025 Next Questions: Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}